MNKD
Mannkind Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Mannkind has 3 disclosed suppliers and 2 disclosed customers in SEC filings.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−5.12%
vs ±9.4% implied · ×0.54
shaded = implied · ▲▼ = realized
Mannkind Corp
3.64
+0.14 · +3.94%
post 3.64 +0.01%
SentenceThe July 2014 Insulin Supply Agreement with Amphastar to manufacture and supply us certain quantities of recombinant human insulin for use in Afrezza was amended in May 2021 and again on December 22, 2023 to purchase certain minimum quantities over a term that currently extends through at least December 31, 2034.
SentenceCurrently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar France Pharmaceuticals S.A.S. ("Amphastar").
MNKD 10-Kaccession 0001193125-26-073516
In December 2025, we supplied our partner in India, Cipla, with an initial shipment of Afrezza to support their launch of Afrezza in India.
MNKD 10-Kaccession 0001193125-26-073516
Linked news
Expected move
Inputs8Q avg ±5.8%·×1.62·rich
spot 3.65exp Nov 6ATM strike 3.5ATM straddle 0.40IV 129%